CK-101, CK-301 data presented at AACR 2017
NEW YORK—Early this quarter, Checkpoint Therapeutics Inc. announced that it had shared preclinical data on CK-101, its third-generation epidermal growth factor receptor inhibitor, and CK-301, its anti-programmed cell death ligand-1 (PD-L1) antibody, at this year’s AACR meeting. Both in vitro and in mouse models, CK-101 was found to be a potent, mutant-selective inhibitor of activating (exon 19 deletion) and resistance mutations (L858R/T790M double mutation) and to inhibit tumor growth as a single agent in a NSCLC model with a single activating mutation (exon 19 deletion), among other findings. Based on these data, Checkpoint initiated a Phase 1/2 clinical trial in September 2016. CK-301 was found to have the potential to induce antibody-dependent cell-mediated cytotoxicity and when tested in assays, demonstrated activity similar to anti-PD-L1’s used as active controls (surrogates of avelumab, atezolizumab or durvalumab). A first-in-human Phase 1 study of CK-301 is expected to begin in 2017.